



REFERENCE LIST

1. Public Health Agency of Canada. *Immunization and Vaccines. Invasive Meningococcal Disease*. Retrieved May 8, 2014 from: www.phac-aspc.gc.ca/im/vpd-mev/meningococcal-eng.php
2. Public Health Agency of Canada. *Update on the use of quadrivalent conjugate vaccines*. Retrieved May 8, 2014 from: http://publications.gc.ca/collections/collection_2013/aspc-phac/HP3-2-39-1-eng.pdf
3. Dubé E. et al. Meningococcal B vaccine acceptability: Results of a longitudinal study in Quebec (Canada). *Vaccine Reports*, 2016; 6: 29-35.
4. Sadrangani M, Bettinger JA, Scheifele DA. How best to describe the risk of meningococcal B infection? *Paed Child Health*, 2013;18(10): 543-544. Retrieved October 23, 2018 from: <https://academic.oup.com/pch/article/18/10/543/2682990>
5. Pfizer Vaccines. Trumenba Product Monograph™. Retrieved September 12, 2018 from: https://www.pfizer.ca/sites/g/files/g10050796/f/201808/Trumenba_PM_214857_24-Jul-2018_E.pdf
6. GlaxoSmithKline Inc. Bexsero Product Monograph®. Retrieved October 3, 2019 from: <https://ca.gsk.com/media/1212390/bexsero.pdf>
7. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). *Vaccine*, 2014;32: 124-130. Retrieved November 23, 2014 from: <https://www.sciencedirect.com/science/article/pii/S0264410X1300409X>
8. Bettinger JA. Personal Communication. 2018, November 8. Email.
9. Nolan T, O’Ryan, M, Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults. *Vaccine*, 2015; 33: 4437-4445. Retrieved October 23, 2018 from: <https://www.sciencedirect.com/science/article/pii/S0264410X1500777X?via%3Dihub>
10. Ostergaard L, Lucaksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. *Vaccine*, 2016; 34: 1465-1471. Retrieved November 22, 2018 from: <https://www.ncbi.nlm.nih.gov/pubmed/26845739>
11. Bryan P, Seabroke S, Wong J, Donegan K, Webb E, Goldsmith C, Vipond C, Feavers I. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. *The Lancet Child & Adolescent Health*, Volume 2, Issue 6, June 2018, Pages 395-403. DOI: [https://doi.org/10.1016/S2352-4642\(18\)30103-](https://doi.org/10.1016/S2352-4642(18)30103-)
12. Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi component meningococcal serogroup B vaccine (4CMenB): The clinical development program. *Drugs*, 2013, December. Retrieved September 12, 2018 from: <http://link.springer.com/article/10.1007%2Fs40265-013-0155-7#page-1>
13. Prymula R, Esposito S, Zucotti GV, Xie F, Toenatto D, Kohl I, Dull PM. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. *Human Vaccines & Immunotherapeutics* 2014;10(7). Retrieved September 12, 2018 from: <http://dx.doi.org/10.4161/hv.28666>